QUANTIFY is an experienced global partner in health economics & outcomes research (HEOR), market access (MA) and other activities related to patient access. Our top priority is to provide high quality services that add value throughout the drug commercialization process by utilizing our unique experience and skillsets. Our core service offerings include:
Real-world evidence & data analytics
QUANTIFY is the leading provider of Nordic RWE. Throughout all stages of research, we deliver high quality, sophisticated results based on our unparalleled knowledge of Nordic data assets and hands-on experience. We also generate RWE across the EU, US and UK. Our approach to RWE generation combines the rigour of academia with the commercial needs of our clients.
Evidence review & synthesis
QUANTIFY has long standing experience in reviewing, interpreting and communicating many types of evidence including published and grey literature. Our team ensures these activities are done systematically, with a focus on usability, to support commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews.
Services
Make the complex simple
News
Looking for an experienced partner to support your evidence generation strategy? Welcome to Quantify!
Last week, ISPOR released their 2022–2023 Top 10 Health Economics and Outcomes Research Trends Report, highlighting high-impact trends in healthcare. These include real world evidence, drug and healthcare pricing, health technology assessment, health data, and artificial intelligence. QUANTIFY is proud to offer experience and expertise in these areas – get in touch with us today to hear more about how we […]
Patients with atopic dermatitis can be accurately identified by algorithm
Quantify’s Gustaf Ortsäter, Kirk Geale and Alexander Rieem Dun have published an observational cohort study which validates an algorithm using skin-specific diagnoses from secondary care and pharmacy-dispensed prescriptions to identify patients with atopic dermatitis.
The study shows that pediatric patients with atopic dermatitis can be accurately identified by the algorithm, but further adjustments are required to identify adult patients. This work is important for future studies that […]
Alzheimer’s disease in a Swedish context
Sweden is a pioneer country when it comes to Alzheimer’s research, and great progress has been made in recent years. Head on over to https://lnkd.in/gVNBKAJd to read an interview with Quantify partner Anders Gustavsson and Karolinska institutet professor Bengt Winblad, on their white paper on Alzheimer’s disease in a Swedish context. (all texts in Swedish).
Health outcomes and risk assessment in chronic liver disease (HERALD)
An exiting new year is ahead of us and Quantify has already kicked it off by attending the #NASH-TAG 2022 conference January 6-8, where Quantify’s Emilie Toresson Grip is presenting the poster ”Health outcomes and risk assessment in chronic liver disease (HERALD): a large Swedish research platform”, co-authored with Quantify’s